# Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis

> **NCT02638259** · PHASE3 · COMPLETED · sponsor: **Sandoz** · enrollment: 376 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GP2015

## Key facts

- **NCT ID:** NCT02638259
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-21
- **Primary completion:** 2016-12-29
- **Final completion:** 2017-06-12
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02638259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02638259, "Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02638259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*